KROS Q3 2020 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$424M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-0.60

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$138M

Total Liabilities

$7M

Stockholders' Equity

$131M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	$0	—
Operating Income	-$12M	-$2M	-413.7%
Net Income	-$12M	-$4M	-239.1%